Ignite Creation Date:
2024-05-05 @ 4:45 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00309179
Status:
COMPLETED
Last Update Posted:
2017-09-14
First Post:
2006-03-29
Brief Title:
A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer Preceded by a Run-in Study in Advanced Solid Tumors
Sponsor:
Eisai Inc
Organization:
Eisai Inc
Study Overview
Official Title:
A Single Arm Phase II Study of the Efficacy Safety and Biomarkers of Activity of E7820 Plus Cetuximab in Advanced Solid Tumors Preceded by a Run-In Study to Determine Safety of the Combination
Status:
COMPLETED
Status Verified Date:
2017-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study proposes to determine the safety of the administration of E7820 plus cetuximab and explore the MTD of the combination in a Phase Ib study In addition the efficacy of this combination will be explored in patients with colorectal cancer in the Phase II proof of concept phase of the study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None